LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | A443654 | 10.0 | uM | LJP6 | 72 | hr | 962 | 173 | 10605 | 0.0164 | -0.0818 |
| MCF 10A | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 962 | 1514 | 10605 | 0.1428 | 0.0572 |
| MCF 10A | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 962 | 6201 | 10605 | 0.5848 | 0.5433 |
| MCF 10A | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 962 | 824 | 10605 | 0.0778 | -0.0143 |
| MCF 10A | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 962 | 1935 | 10605 | 0.1825 | 0.1010 |
| MCF 10A | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 962 | 1004 | 10605 | 0.0947 | 0.0044 |
| MCF 10A | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 962 | 979 | 10605 | 0.0924 | 0.0018 |
| MCF 10A | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 962 | 2440 | 10605 | 0.2301 | 0.1533 |
| MCF 10A | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 962 | 586 | 10605 | 0.0553 | -0.0390 |
| MCF 10A | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 962 | 1162 | 10605 | 0.1096 | 0.0207 |
| MCF 10A | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 962 | 208 | 10605 | 0.0196 | -0.0782 |
| MCF 10A | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 962 | 676 | 10605 | 0.0638 | -0.0296 |
| MCF 10A | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 962 | 326 | 10605 | 0.0307 | -0.0660 |
| MCF 10A | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 962 | 279 | 10605 | 0.0263 | -0.0708 |
| MCF 10A | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 962 | 8827 | 10605 | 0.8323 | 0.8156 |
| MCF 10A | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 962 | 9395 | 10605 | 0.8860 | 0.8746 |
| MCF 10A | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 962 | 6114 | 10605 | 0.5765 | 0.5343 |
| MCF 10A | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 1392 | 10605 | 0.1313 | 0.0446 |
| MCF 10A | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 1247 | 10605 | 0.1177 | 0.0296 |
| MCF 10A | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 782 | 10605 | 0.0737 | -0.0187 |
| MCF 10A | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 962 | 514 | 10605 | 0.0485 | -0.0464 |
| MCF 10A | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 921 | 10605 | 0.0869 | -0.0042 |
| MCF 10A | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 962 | 11123 | 10605 | 1.0489 | 1.0537 |
| MCF 10A | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 1501 | 10605 | 0.1416 | 0.0559 |
| MCF 10A | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 962 | 930 | 10605 | 0.0878 | -0.0033 |